TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04040010

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Colostrum supplementation for bone loss
Description: Participants in the interventions groups (i.e. colostrum supplementation) will take a colostrum mixture for 5 months (5 times per week; a total of 250ml per day in liquid form). Participants in the placebo groups (i.e. controls) will be taking a placebo mixture (a total of 250ml per day in liquid form per dose) for the same period of time.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Colostrum supplementation for bone loss
Description: Participants in the interventions groups (i.e. colostrum supplementation) will take a colostrum mixture for 5 months (5 times per week; a total of 250ml per day in liquid form). Participants in the placebo groups (i.e. controls) will be taking a placebo mixture (a total of 250ml per day in liquid form per dose) for the same period of time.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Colostrum supplementation for bone loss
Description: Participants in the interventions groups (i.e. colostrum supplementation) will take a colostrum mixture for 5 months (5 times per week; a total of 250ml per day in liquid form). Participants in the placebo groups (i.e. controls) will be taking a placebo mixture (a total of 250ml per day in liquid form per dose) for the same period of time.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Colostrum supplementation for bone loss
Description: Participants in the interventions groups (i.e. colostrum supplementation) will take a colostrum mixture for 5 months (5 times per week; a total of 250ml per day in liquid form). Participants in the placebo groups (i.e. controls) will be taking a placebo mixture (a total of 250ml per day in liquid form per dose) for the same period of time.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Colostrum supplementation for bone loss
Description: Participants in the interventions groups (i.e. colostrum supplementation) will take a colostrum mixture for 5 months (5 times per week; a total of 250ml per day in liquid form). Participants in the placebo groups (i.e. controls) will be taking a placebo mixture (a total of 250ml per day in liquid form per dose) for the same period of time.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Colostrum supplementation for bone loss
Description: Participants in the interventions groups (i.e. colostrum supplementation) will take a colostrum mixture for 5 months (5 times per week; a total of 250ml per day in liquid form). Participants in the placebo groups (i.e. controls) will be taking a placebo mixture (a total of 250ml per day in liquid form per dose) for the same period of time.
Study: NCT03491748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX0282
Description: Oral Gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX0282
Description: Oral Gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX0282
Description: Oral Gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX0282
Description: Oral Gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX0282
Description: Oral Gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX0282
Description: Oral Gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX0282
Description: Oral Gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX0282
Description: Oral Gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX0282
Description: Oral Gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX0282
Description: Oral Gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Gelatin capsules
Study: NCT02768415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Vinorelbine
Study: NCT04422366

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha)
Description: Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GARDASIL®
Description: Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule
Study: NCT02997839

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: sleep disruption
Description: Group two will have interrupted sleep at time periods of 2 hours post operatively.~Group two will be woken every 2 hours, which is the standard NCCU protocol.
Study: NCT01930435

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sterile Humidification Device
Description: This is a personal humidification device. It is hand held and produces sterile warm vapor.
Study: NCT03180879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test - RB ibuprofen acid orodispersible tablets
Description: RB ibuprofen acid orodispersible tablets, 2 x 200 mg, single dose, oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test - RB ibuprofen acid orodispersible tablets
Description: RB ibuprofen acid orodispersible tablets, 2 x 200 mg, single dose, oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test - RB ibuprofen acid orodispersible tablets
Description: RB ibuprofen acid orodispersible tablets, 2 x 200 mg, single dose, oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test - RB ibuprofen acid orodispersible tablets
Description: RB ibuprofen acid orodispersible tablets, 2 x 200 mg, single dose, oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test - RB ibuprofen acid orodispersible tablets
Description: RB ibuprofen acid orodispersible tablets, 2 x 200 mg, single dose, oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test - RB ibuprofen acid orodispersible tablets
Description: RB ibuprofen acid orodispersible tablets, 2 x 200 mg, single dose, oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference - RB Nurofen ibuprofen acid tablets
Description: RB Nurofen ibuprofen acid tablets, 2 x 200 mg, single dose, oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference - RB Nurofen ibuprofen acid tablets
Description: RB Nurofen ibuprofen acid tablets, 2 x 200 mg, single dose, oral.
Study: NCT02196376

Intervention type: OTHER
Intervention: History
Description: the physician / PI will conduct a history that may include: demographics Framingham risk factors metabolic diseases inflammatory diseases autoimmune disorders review of medications date of last menstrual period (females) family history of autonomic disorders Onset of postural orthostatic tachycardia syndrome

Intervention type: OTHER
Intervention: History
Description: the physician / PI will conduct a history that may include: demographics Framingham risk factors metabolic diseases inflammatory diseases autoimmune disorders review of medications date of last menstrual period (females) family history of autonomic disorders Onset of postural orthostatic tachycardia syndrome
Study: NCT03180879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference - RB Nurofen ibuprofen acid tablets
Description: RB Nurofen ibuprofen acid tablets, 2 x 200 mg, single dose, oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference - RB Nurofen ibuprofen acid tablets
Description: RB Nurofen ibuprofen acid tablets, 2 x 200 mg, single dose, oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference - RB Nurofen ibuprofen acid tablets
Description: RB Nurofen ibuprofen acid tablets, 2 x 200 mg, single dose, oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference - RB Nurofen ibuprofen acid tablets
Description: RB Nurofen ibuprofen acid tablets, 2 x 200 mg, single dose, oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator - Dolormin ibuprofen lysine tablets
Description: Dolormin ibuprofen lysine tablets 2 x 342 mg (each 342 mg tablet contains 200 mg ibuprofen), single dose, oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator - Dolormin ibuprofen lysine tablets
Description: Dolormin ibuprofen lysine tablets 2 x 342 mg (each 342 mg tablet contains 200 mg ibuprofen), single dose, oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator - Dolormin ibuprofen lysine tablets
Description: Dolormin ibuprofen lysine tablets 2 x 342 mg (each 342 mg tablet contains 200 mg ibuprofen), single dose, oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator - Dolormin ibuprofen lysine tablets
Description: Dolormin ibuprofen lysine tablets 2 x 342 mg (each 342 mg tablet contains 200 mg ibuprofen), single dose, oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator - Dolormin ibuprofen lysine tablets
Description: Dolormin ibuprofen lysine tablets 2 x 342 mg (each 342 mg tablet contains 200 mg ibuprofen), single dose, oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator - Dolormin ibuprofen lysine tablets
Description: Dolormin ibuprofen lysine tablets 2 x 342 mg (each 342 mg tablet contains 200 mg ibuprofen), single dose, oral.
Study: NCT04498247

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V591
Description: 1 or 2 ascending doses of V591 will be administered via intramuscular (IM) injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V591
Description: 1 or 2 ascending doses of V591 will be administered via intramuscular (IM) injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V591
Description: 1 or 2 ascending doses of V591 will be administered via intramuscular (IM) injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V591
Description: 1 or 2 ascending doses of V591 will be administered via intramuscular (IM) injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V591
Description: 1 or 2 ascending doses of V591 will be administered via intramuscular (IM) injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V591
Description: 1 or 2 ascending doses of V591 will be administered via intramuscular (IM) injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V591
Description: 1 or 2 ascending doses of V591 will be administered via intramuscular (IM) injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V591
Description: 1 or 2 ascending doses of V591 will be administered via intramuscular (IM) injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V591
Description: 1 or 2 ascending doses of V591 will be administered via intramuscular (IM) injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V591
Description: 1 or 2 ascending doses of V591 will be administered via intramuscular (IM) injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (0.9% sodium chloride) administered via IM injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (0.9% sodium chloride) administered via IM injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (0.9% sodium chloride) administered via IM injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (0.9% sodium chloride) administered via IM injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (0.9% sodium chloride) administered via IM injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (0.9% sodium chloride) administered via IM injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (0.9% sodium chloride) administered via IM injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (0.9% sodium chloride) administered via IM injection.
Study: NCT02196376

Intervention type: OTHER
Intervention: Physical
Description: the physical exam will include: height weight orthostatic vitals (heart rate and blood pressure), supine and standing for up to 10 minutes.~Beighton Criteria for Join Hypermobility Syndrome Dependent acrocyanosis

Intervention type: OTHER
Intervention: Physical
Description: the physical exam will include: height weight orthostatic vitals (heart rate and blood pressure), supine and standing for up to 10 minutes.~Beighton Criteria for Join Hypermobility Syndrome Dependent acrocyanosis
Study: NCT04498247

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (0.9% sodium chloride) administered via IM injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (0.9% sodium chloride) administered via IM injection.
Study: NCT02196376

Intervention type: OTHER
Intervention: blood draw
Description: blood will be drawn for: antibodies regulating cardiovascular function inflammatory markers~no more than 15 ml (1 TBSP) will be drawn.

Intervention type: OTHER
Intervention: blood draw
Description: blood will be drawn for: antibodies regulating cardiovascular function inflammatory markers~no more than 15 ml (1 TBSP) will be drawn.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: The questionnaires will be completed directly online (web-based interface) using a personalized link that will be provided to the subjects after they give their informed consent. These will be created in a REDCap-Survey environment, with the data collected and stored on a password-protected, HIPAA-compliant, secure computer server.~The following questionnaires will be conducted:~RAND-36 Health Thermometer Chalder Fatigue Scale Daily diary of Fatigue Symptoms - Fibromyalgia Pain Detect Questionnaire Orthostatic Grading Scale COMPASS-31
Study: NCT03469349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Actovegin
Description: Actovegin intravenous infusion and tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Actovegin placebo-matching intravenous infusion and tablets.
Study: NCT04049903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP0310
Description: MP0310 will be examined for safety, tolerability, PK, and PD activity in subjects with advanced solid tumors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP0310
Description: MP0310 will be examined for safety, tolerability, PK, and PD activity in subjects with advanced solid tumors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP0310
Description: MP0310 will be examined for safety, tolerability, PK, and PD activity in subjects with advanced solid tumors
Study: NCT03748836

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALPN-101
Description: Single or multiple doses of ALPN-101 delivered via intravenous or subcutaneous injection. Ascending dose levels will be evaluated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALPN-101
Description: Single or multiple doses of ALPN-101 delivered via intravenous or subcutaneous injection. Ascending dose levels will be evaluated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single or multiple doses of placebo delivered via intravenous or subcutaneous injection, matched to ALPN-101 cohorts.
Study: NCT02196376

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: The questionnaires will be completed directly online (web-based interface) using a personalized link that will be provided to the subjects after they give their informed consent. These will be created in a REDCap-Survey environment, with the data collected and stored on a password-protected, HIPAA-compliant, secure computer server.~The following questionnaires will be conducted:~RAND-36 Health Thermometer Chalder Fatigue Scale Daily diary of Fatigue Symptoms - Fibromyalgia Pain Detect Questionnaire Orthostatic Grading Scale COMPASS-31
Study: NCT04867993

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amikacin
Description: 15 mg/kg/36h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amikacin
Description: 15 mg/kg/36h
Study: NCT02175134

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood and Ascites ELISPOT
Study: NCT01785225

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A product type of the modified commercial drape Tegaderm (R)
Description: We test if a product type of the modified commercial drape Tegaderm(R) can bee used when taking blood samples under the guidance af ultrasound. The drape is used to keep the puncture area sterile and clean of ultrasound gel.
Study: NCT02523924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL
Description: 18F-DCFPyL PET/CT
Study: NCT01321138

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral nerve block
Description: The femoral nerve block will be performed with ultrasound 30 minutes before the intervention

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PCA morphine
Description: Postoperative analgesia with self-administration iv morphine
Study: NCT02684409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PROT-CL-NP101-015.01
Study: NCT04178707

Intervention type: DEVICE
Group type: OTHER
Intervention: OnZurf Probe, Senzime AB, Uppsala, Sweden
Description: Probe is inserted into the fistula and measurements are made of the inner environment.
Study: NCT01735344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril Tablets 40 mg
Description: 40 mg tablet once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril
Description: 40 mg tablet once a day
Study: NCT03429751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 ml/Kg/h crystalloid
Description: Lung ultrasound 8 region assessment using curvilinear 2 to 5 megahertz prob after receiving 30 ml/Kg/h crystalloid in addition to losses for maximum 3 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 ml/Kg/h crystalloid
Description: Lung ultrasound 8 region assessment using curvilinear 2 to 5 megahertz prob after receiving 10 ml/Kg/h crystalloid in addition to losses for maximum 3 hours.
Study: NCT02703272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Participants will receive Ibrutinib (dose 240 mg/m\^2 /329 mg/m\^2 per day) during part 1 and part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Participants will receive Ibrutinib (dose 240 mg/m\^2 /329 mg/m\^2 per day) during part 1 and part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive a cumulative dose of rituximab 750 mg/m\^2 as a part of RICE/RVICI regimen in part 1 and part 2 per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive a cumulative dose of rituximab 750 mg/m\^2 as a part of RICE/RVICI regimen in part 1 and part 2 per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Participants will receive a cumulative dose of Ifosfamide 9 g/m\^2 and 10 g/m\^2 as a part of RICE and RVICI regimen respectively in part 1 and part 2 per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Participants will receive a cumulative dose of Ifosfamide 9 g/m\^2 and 10 g/m\^2 as a part of RICE and RVICI regimen respectively in part 1 and part 2 per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Participants will receive a cumulative dose of carboplatin 635 mg/m\^2 and 800 mg/m\^2 as a part of RICE and RVICI regimen respectively in part 1 and part 2 per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Participants will receive a cumulative dose of carboplatin 635 mg/m\^2 and 800 mg/m\^2 as a part of RICE and RVICI regimen respectively in part 1 and part 2 per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Participants will receive a cumulative dose of etoposide 300 mg/m\^2 in part 1 and part 2 as a part of RICE regimen per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Participants will receive a cumulative dose of etoposide 300 mg/m\^2 in part 1 and part 2 as a part of RICE regimen per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Participants will receive a cumulative dose of vincristine 1.6 mg/m\^2 in part 1 and part 2 as a part of RVICI regimen per cycle.
Study: NCT03748836

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single or multiple doses of placebo delivered via intravenous or subcutaneous injection, matched to ALPN-101 cohorts.
Study: NCT01133574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV354 capsules
Description: 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV354 capsules
Description: 60 mg